Antisynthetase syndrome: Clinical Trials

15 trials for Antisynthetase syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 recruiting, 4 completed, 4 unknown, 1 active not recruiting. 4 Phase 3, 3 Phase 2, 1 Early Phase 1, 1 Not applicable, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 34Active not recruiting 1, Completed 1, Enrolling by invitation 1, Unknown 1
Phase 23Active not recruiting 1, Completed 1, Recruiting 1
Early Phase 11Recruiting 1
Not applicable1Recruiting 1
Phase 11Recruiting 1

Follow Antisynthetase syndrome: new trials by email Literature Review of Antisynthetase syndrome trials Research Report on Antisynthetase syndrome

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome
JAK Inhibitor, Calcineurin Inhibitors (CNI) - Antisynthetase Syndrome, Interstitial Lung Disease (ILD)
Not applicableRecruitingChina-Japan Friendship Hospital802026-05-182026-06-03
Descartes-08 in Autoantibody Myositis
Descartes-08, Placebo - Antisynthetase Syndrome
Phase 2RecruitingCartesian Therapeutics602026-04-282026-08-17
An Exploratory Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid Arthritis
anti CD19 CAR NK cells - Antisynthetase Syndrome, Rheumatoid Arthritis
Early Phase 1RecruitingThe First Affiliated Hospital with Nanjing Medical University242025-05-202025-04-30
BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy
ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR-T - Inflammatory Myopathy
Phase 1RecruitingiCell Gene Therapeutics102025-03-202026-07-20
Evaluation of Antigen-specific T Cells in Patients With Antisynthetase Syndrome and Interstitial Lung Disease
BAL antigen-specific Th1 cells and Th17 cells, ILC and MAIT - Antisynthetase Syndrome
UnknownCentral Hospital, Nancy, France242024-08-262024-08-27
Evaluation of Circulating Neutrophils in Antisynthetase Syndrome
circulating neutrophils - Antisynthetase Syndrome
CompletedCentral Hospital, Nancy, France892024-01-012026-04-20
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
Efgartigimod PH20 SC - Myositis, Active Idiopathic Inflammatory Myopathy
Phase 3Enrolling by invitationargenx2402023-09-122026-10-16
Evaluation of Peripheral Neutrophils in Antisynthetase Syndrome
Antisynthetase Syndrome
CompletedCentral Hospital, Nancy, France402023-02-012023-08-03
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
EFG PH20 SC, PBO - Active Idiopathic Inflammatory Myopathy, Myositis
Phase 2 / Phase 3Completedargenx2652022-10-122026-09-21
Tocilizumab in Refractory ASS-ILD
Tociliuzumab - Antisynthetase Syndrome, Tocilizumab
CompletedHu Yinan1112022-01-012026-06-23
Add-on Intravenous Immunoglobulins in Early Myositis
Immune Globulin Intravenous (Human), Placebo - Inflammatory Myopathy, Idiopathic, Dermatomyositis
Phase 2 / Phase 3Active not recruitingAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)442021-09-132026-02-27
Evaluation of Interstitial Lung Disease Severity in Patients With Antisynthetase Syndrome According to Specific Autoantibodies Profile
Follow-up - Antisynthetase Syndrome
UnknownCentral Hospital, Nancy, France2002021-06-012021-06-14
Association Between Cancer and Anti-synthetase Syndrome
Antisynthetase Syndrome
UnknownCentral Hospital, Nancy, France2002021-04-012021-06-28
Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease
Cyclophosphamide and azathioprine, Tacrolimus - Antisynthetase Syndrome (ASS), Interstitial Lung Disease
Phase 3UnknownAssistance Publique - Hôpitaux de Paris762021-02-052021-02-09
Optimizing Treatment on Idiopathic Inflammatory Myopathies
Intravenous Infusion - Idiopathic Inflammatory Myopathies
RecruitingUniversity of Sao Paulo602005-01-012024-12-05

Narrower conditions

Myositis (7)  ·  Dermatomyositis (5)  ·  Polymyositis (5)  ·  Lung Diseases, Interstitial (3)  ·  Arthritis, Rheumatoid (1)  ·  Neoplasms (1)

Broader conditions

Musculoskeletal Diseases (8)  ·  Muscular Diseases (7)  ·  Nervous System Diseases (7)  ·  Neuromuscular Diseases (7)  ·  Connective Tissue Diseases (6)  ·  Skin and Connective Tissue Diseases (6)  ·  Skin Diseases (5)  ·  Lung Diseases (3)  ·  Respiratory Tract Diseases (3)  ·  Arthritis (1)  ·  Autoimmune Diseases (1)  ·  Immune System Diseases (1)  ·  Joint Diseases (1)  ·  Rheumatic Diseases (1)

Interventions

Azathioprine (1)  ·  Calcineurin Inhibitors (1)  ·  Cyclophosphamide (1)  ·  Dosage Forms (1)  ·  Immunoglobulins, Intravenous (1)  ·  Infusions, Intravenous (1)  ·  Janus Kinase Inhibitors (1)  ·  Sodium Chloride (1)  ·  Tacrolimus (1)  ·  tocilizumab (1)

Sponsors

Central Hospital, Nancy, France (5)  ·  argenx (2)  ·  Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Cartesian Therapeutics (1)  ·  China-Japan Friendship Hospital (1)  ·  Hu Yinan (1)  ·  The First Affiliated Hospital with Nanjing Medical University (1)  ·  University of Sao Paulo (1)  ·  iCell Gene Therapeutics (1)

Countries

France (7)  ·  China (6)  ·  Netherlands (3)  ·  United States (3)  ·  Argentina (2)  ·  Austria (2)  ·  Belgium (2)  ·  Bulgaria (2)  ·  Cyprus (2)  ·  Czechia (2)  ·  Denmark (2)  ·  Georgia (2)  ·  Germany (2)  ·  Greece (2)  ·  Ireland (2)

Top investigators

Paul Decker, MD (2)  ·  Samuel K Shinjo, PhD (1)  ·  Thomas Moulinet, MD (1)

NIH funding

2016 (1)